Pacific Biosciences of California, Inc.

PACB

US69404D1081

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 10:23:23 2024-04-26 am EDT			5-day change	1st Jan Change
1.475 ^USD	+6.88%		-3.83%	-84.80%

Apr. 22	JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	MT
Apr. 18	Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	MT

Pacific Biosciences of California, Inc. announced that it has received $299.999993 million in funding from a group of investors

September 19, 2021

On September 20, 2021, Pacific Biosciences of California, Inc. closed the transaction.

Latest news about Pacific Biosciences of California, Inc.

JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	Apr. 22	MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	Apr. 18	MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	Apr. 18	MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating	Apr. 17	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
Sector Update: Health Care	Apr. 16	MT
Pacific Biosciences of California Q1 Revenue Expected to Be Flat Year Over Year; Guidance Lowered; Shares Sink	Apr. 16	MT
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024	Apr. 16	CI
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating	Apr. 10	MT
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes	Mar. 27	CI
Transcript : Pacific Biosciences of California, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM	Mar. 12
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions	Mar. 12	CI
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating	Feb. 16	MT
Pacific Biosciences of California Q4 Non-GAAP Loss Narrows, Revenue Rises; Shares Drop After Hours	Feb. 15	MT
Transcript : Pacific Biosciences of California, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q4 Revenue $58.4M, vs. Street Est of $58.3M	Feb. 15	MT
Pacific Biosciences of California, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale	Feb. 05	CI
PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions	Jan. 15	CI
Transcript : Pacific Biosciences of California, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	Jan. 10
Pacific Biosciences Posts Higher Preliminary Q4, Full-Year 2023 Revenue	Jan. 08	MT
UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating	Jan. 02	MT
Guggenheim Initiates Pacific Biosciences of California With Neutral Rating	Dec. 14	MT
Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board	Dec. 11	CI
Pacific Biosciences of California Shares Rise After UBS Upgrade	Nov. 17	MT

Chart Pacific Biosciences of California, Inc.

Duration

Period

Chart Pacific Biosciences of California, Inc.

More charts

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Pacific Biosciences of California, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.38 USD

Average target price

5.818 USD

Spread / Average Target

+321.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	-84.80%	376M
THERMO FISHER SCIENTIFIC	+7.93%	218B
DANAHER CORPORATION	+6.22%	182B
INTUITIVE SURGICAL, INC.	+11.17%	132B
BOSTON SCIENTIFIC CORPORATION	+26.79%	108B
EDWARDS LIFESCIENCES CORPORATION	+11.30%	52.98B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.59B
AGILENT TECHNOLOGIES, INC.	-1.35%	39.96B
GE HEALTHCARE TECHNOLOGIES INC.	+11.12%	39.22B
RESMED, INC.	+21.96%	26.94B

Other Advanced Medical Equipment & Technology